Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Innoviva Strategic Opportunities is a wholly-owned subsidiary of Innoviva, Inc., managing strategic investments in biotech and pharma—including direct operational control and financing (e.g., $35M credit to Armata Pharmaceuticals, which is advancing Phase 2 bacteriophage therapies). Its parent holds royalty streams from marketed respiratory drugs (e.g., Trelegy, Anoro, Breo), and through acquisitions (e.g., Entasis, La Jolla) and loans, Innoviva Strategic Opportunities enables clinical development of novel anti-infectives and critical care assets
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Innoviva Strategic Opportunities.